Characterization of antimicrobial resistance among Escherichia coli O111 isolates of animal and human origin

Fifty isolates of Escherichia coli serogroup O111 recovered from humans and various animal species over a 24-year period (1976-1999) were examined for typical virulence-associated factors and susceptibilities to antimicrobials of human and veterinary significance. Nine H (flagellar) types were identified including nonmotile (n = 24), 32 (n = 12), negative (n = 5), and 56 (n = 3). Thirty-five (70%) isolates possessed at least one Shiga-toxin-producing E. coli (STEC)-associated virulence determinants (eae, stxl, stx2, hlyA) via PCR analysis. Of these 35 isolates, 20 possessed eae, stxl, and hlyA genes, whereas three isolates possessed eae, stxl, stx2, and hylA genes. Multiple antibiotic resistance was observed in 70% of the 50 E. coli O111 isolates. The majority of isolates displayed resistance to streptomycin, sulfamethoxazole, tetracycline, and kanamycin. Bacterial resistance to ampicillin, gentamicin, chloramphenicol, trimethoprim and apramycin was also observed. Integrons were identified in 23 (46%) of the E. coli isolates assayed, with a 1-kb amplicon being most frequently observed. DNA sequencing of these integrons revealed the presence of the aadA gene, encoding resistance to streptomycin. Two integrons of 1.5 and 2 kb contained the aadA2 and either dfrI or dfrXII genes, encoding resistance to streptomycin and trimethoprim, respectively. Integrons were also identified from isolates dating back to 1982. Isolates were further genetically characterized via ribotyping, which identified 15 distinct ribogroups, with 62% of isolates clustering into four major ribogroups. Certain riboprint patterns from different animal species, including humans, were observed in isolates spanning the 24-year collection period, suggesting the dissemination of specialized pathogenic O111 clones.     

The combination of growth hormone with hepatocyte growth factor alters the acute phase response.

Recombinant human growth hormone (rhGH) and hepatocyte growth factor (HGF) have both been shown to individually modulate hepatic acute phase reactant proteins and cytokine expression following trauma through different pathways. Recombinant hGH has also been shown to decrease serum and hepatic HGF concentrations after a thermal injury. We hypothesized that the combination of rhGH plus HGF improves the burn-induced acute phase response. Fifty-six male Sprague-Dawley rats received a 60% TBSA third-degree scald burn and were randomly divided to receive either rhGH (2.5 mg/kg/day sc.) plus HGF (200 microg/kg i.v. every 12 h) or placebo (saline). Rats were sacrificed on post-burn days 1, 2, 5, or 7 and serum constitutive and acute phase proteins, TNF-alpha, IL-1beta, IL-6 and liver total protein measured. Hepatic cytokine gene expression, triglyceride concentration, and hepatocyte proliferation were also measured. In rats receiving rhGH/HGF, serum albumin increased on days 5 and 7 and transferrin on day 7 after burn compared to placebo (P<0.05). Haptoglobin decreased 5 days after burn compared to placebo (P<0.05). RhGH/HGF increased serum TNF-alpha on day 2 after burn, while it decreased serum IL-1beta on day 1 after burn compared with placebo (P<0.05). RhGH/HGF had no effect on hepatic cytokine gene expression compared with placebo. Liver total protein content and hepatocyte proliferation increased on days 1, 2, 5, and 7 after burn with rhGH/HGF treatment (P<0.05). These findings indicate that rhGH in combination with HGF exert additive effects on constitutive hepatic proteins and partial inhibitory effects on acute phase protein and cytokine expression. RhGH/HGF has a strong mitogenic effect on hepatocytes.     

A family of conserved bacterial effectors inhibits salicylic acid-mediated basal immunity and promotes disease necrosis in plants

Salicylic acid (SA)-mediated host immunity plays a central role in combating microbial pathogens in plants. Inactivation of SA-mediated immunity, therefore, would be a critical step in the evolution of a successful plant pathogen. It is known that mutations in conserved effector loci (CEL) in the plant pathogens Pseudomonas syringae (the Delta CEL mutation), Erwinia amylovora (the dspA/E mutation), and Pantoea stewartii subsp. stewartii (the wtsE mutation) exert particularly strong negative effects on bacterial virulence in their host plants by unknown mechanisms. We found that the loss of virulence in Delta CEL and dspA/E mutants was linked to their inability to suppress cell wall-based defenses and to cause normal disease necrosis in Arabidopsis and apple host plants. The Delta CEL mutant activated SA-dependent callose deposition in wild-type Arabidopsis but failed to elicit high levels of callose-associated defense in Arabidopsis plants blocked in SA accumulation or synthesis. This mutant also multiplied more aggressively in SA-deficient plants than in wild-type plants. The hopPtoM and avrE genes in the CEL of P. syringae were found to encode suppressors of this SA-dependent basal defense. The widespread conservation of the HopPtoM and AvrE families of effectors in various bacteria suggests that suppression of SA-dependent basal immunity and promotion of host cell death are important virulence strategies for bacterial infection of plants.     

Assessment of phenotypic and genotypic diversity of Escherichia coli shed by healthy lactating dairy cattle

A study was conducted to assess the diversity among fecal Escherichia coli from healthy lactating cattle. E. coli (n = 100) isolates from 10 healthy lactating dairy cows of a Pennsylvania dairy herd were examined for phenotypic and genotypic characteristics. Results revealed 26, 58, 10, and 6 E. coli isolates belonged to phylogenetic groups A, B1, B2, and D respectively. Overall, 63 serotypes, nine antibiotic resistance profiles, and 65 pulsed-field gel electrophoresis (PFGE) profiles were observed among the 100 isolates. Based on the combination of phenotypic and genotypic characteristics, the 100 E. coli isolates were classified into 76 clonal types. The numbers of different phenotypic and genotypic characteristics of E. coli were observed for each cow at ranges of 2-10, 1- 4, 2-10, and 4-10 for serotypes, antibiograms, PFGE profiles, and clonal types, respectively. The Chao1 estimator was used to estimate diversity among fecal E. coli. It was estimated that a range of 3-55, 1- 4, 2-55, and 8-55 fecal isolates from one cow would be required to include all possible types of E. coli based on serotype, antibiotic resistance profile, PFGE profile, and clonal type respectively. Based on the findings of the study it can be inferred that 1) dairy cattle should be considered as a significant reservoir of genotypically and phenotypically diverse E. coli, and 2) epidemiological investigations that focus on commensal bacteria should take into consideration the diversity within the species being investigated; if not addressed adequately, inappropriate sample size could lead to inaccurate study findings.     

Antimicrobial resistance of Escherichia coli O26, O103, O111, O128, and O145 from animals and humans

Susceptibilities to fourteen antimicrobial agents important in clinical medicine and agriculture were determined for 752 Escherichia coli isolates of serotypes O26, O103, O111, O128, and O145. Strains of these serotypes may cause urinary tract and enteric infections in humans and have been implicated in infections with Shiga toxin-producing E. coli (STEC). Approximately 50% of the 137 isolates from humans were resistant to ampicillin, sulfamethoxazole, cephalothin, tetracycline, or streptomycin, and approximately 25% were resistant to chloramphenicol, trimethoprim-sulfamethoxazole, or amoxicillin-clavulanic acid. Approximately 50% of the 534 isolates from food animals were resistant to sulfamethoxazole, tetracycline, or streptomycin. Of 195 isolates with STEC-related virulence genes, approximately 40% were resistant to sulfamethoxazole, tetracycline, or streptomycin. Findings from this study suggest antimicrobial resistance is widespread among E. coli O26, O103, O111, O128, and O145 inhabiting humans and food animals.     

Impact of vaccination on SARS-CoV-2 infection:Experience from a tertiary care hospital

Ever since the world has been engulfed by the COVID-19 pandemic,caused by SARS-CoV-2 virus,humanity has gone through untold miseries.There has been a widespread...     

Escherichia coli Sequence Type ST131 as an Emerging Fluoroquinolone-Resistant Uropathogen among Renal Transplant Recipients

Among 40 Escherichia coli urine isolates from renal transplant recipients (Galveston, TX, 2003 to 2005), sequence type ST131 (O25:H4) was highly prevalent (representing 35% of isolates overall and 60% of fluoroquinolone-resistant isolates), virulent appearing, antimicrobial resistant (but extended-spectrum-cephalosporin susceptible), and associated with black race. Pulsotypes were diverse; some were linked to other locales. ST131 emerged significantly during the study period. These findings suggest that E. coli ST131 may constitute an important new multidrug-resistant threat to renal transplant recipients.Renal transplant recipients are at increased risk for urinary tract infection (UTI), which can cause local and systemic manifestations and precipitate acute allograft injury (AAI) (14-17). Escherichia coli is the most common cause of UTI among renal transplant recipients (14-17). The increasing prevalence of resistance to trimethoprim-sulfamethoxazole (TMP-SMX) and other antimicrobials in E. coli threatens the utility of posttransplant TMP-SMX prophylaxis and makes acute UTI therapy more challenging.A recent survey of E. coli urine isolates from renal transplant recipients at the University of Texas, Galveston, TX (2003 to 2005), identified a high prevalence of serogroup O25 (15), which was associated with levofloxacin resistance (J. Rice, unpublished data). Since O25 and fluoroquinolone (FQ) resistance characterize an emerging clonal group of pathogenic E. coli designated sequence type ST131 (3, 12), which is associated with the CTX-M-15 extended-spectrum beta-lactamase, we assessed the prevalence, characteristics, and clinical correlates of ST131 within this distinctive population.     

Recombinant human growth hormone alters acute phase reactant proteins, cytokine expression, and liver morphology in burned rats.

BACKGROUND: The effects of exogenous recombinant human growth hormone (rhGH) on hepatic acute phase reactant proteins, cytokine expression, and liver morphology were studied in thermally injured rats to define whether rhGH alters the acute phase response. MATERIALS AND METHODS: Sprague-Dawley rats (56 males) receiving a 60% TBSA third-degree scald burn were randomly divided into two groups to receive either 2.5 mg/kg/day sc rhGH or saline. Rats were sacrificed on Postburn Days 1, 2, 5, and 7. Serum acute phase reactant proteins and cytokines TNF-alpha, IL-1alpha, IL-1beta, and IL-6 were measured. Hepatocyte proliferation, hepatic cytokine gene expression, and liver protein concentrations were determined. RESULTS: Recombinant hGH increased serum albumin on Days 5 and 7 after burn (P < 0.05). Serum haptoglobin and alpha1-acid glycoprotein levels decreased at 2, 5, and 7 days after burn compared to saline (P < 0.05). In rats treated with rhGH, serum IL-1beta decreased 1 day postburn, while serum TNF-alpha increased 5 days after burn compared to saline (P < 0.05). Serum IL-6 and IL-1alpha did not change. Hepatic RNA levels for TNF-alpha were significantly elevated on Day 1 postburn compared to saline (P < 0. 05). Hepatic protein content increased on Days 2, 5, and 7 postburn compared to saline (P < 0.05). Hepatocyte proliferation in rhGH-treated rats increased on Day 5 after burn (P < 0.05). CONCLUSION: Data indicate that rhGH alters the hepatic acute phase response by decreasing type I acute phase proteins and modulating IL-1-like cytokine expression. These changes are associated with increased hepatocyte mitosis and serum and total liver protein concentrations.